UCSF Wins Big, From Gamechangers to Startups to Life Achievement Special shoutout to ImmunoX member, Dr. Susan Lynch, recipient of the Disruptive Research Award! ucsf.edu/news/2026/09/432636…

UCSF-Led Group Awarded $9 Million for Heart Inflammation Research Congratulations to ImmunoX member, Dr. Javid Moslehi, and team on this big win! ucsf.edu/news/2026/08/432481…

Our founding director Jeff Bluestone, PhD receives UCSF's highest honor, the 2026 UCSF Medal ucsf.edu/news/2026-ucsf-meda…

Scientists at Gladstone and @UCSF developed a method to genetically edit myeloid cells, immune cells that act as the body’s first responders. @NatureBiotech @jccarnevale bit.ly/3SGx5Fw

Excited to share this massive (60+ co-authors!) team effort describing the clinical correlates of anti-CD320 in idiopathic myelopathy

Incredibly excited to share the first major paper from my lab @carnevale_lab led by postdoc Qi Liu @GladstoneInst @UCSF executing the first ever genome-wide in vivo screens for genetic modifications to enhance human T cell therapies for solid tumors. Now in @Nature: nature.com/articles/s41586-0…

👏 🔬 CRI is proud to announce the 2026 CLIP and Tech Impact Award projects, supporting innovative research and cutting-edge technologies that have the potential to accelerate the next generation of cancer immunotherapies. Learn more: bit.ly/4hr5ty8 #CancerResearcher

🚨 New @NIH support for @UCSF General Surgery Resident Dr. Eva Mae Gillis-Buck. Her project, "Defining the role of RORγt-lineage antigen-presenting cells in maternal-fetal tolerance," has received funding from the #NIAID to advance maternal-fetal immunology & healthy pregnancy👏

Promising new research from PICI member researcher @LuRongze at the @NeurosurgUCSF highlights a potential new therapeutic approach for aggressive, treatment-resistant pediatric brain tumors. Published in the @jclinicalinvest, the research shows that targeting PP2A induced tumor cell senescence, strengthened anti-tumor immune responses, and significantly extended survival in preclinical medulloblastoma models. The findings identify PP2A as a promising therapeutic target for high-risk disease. By helping make difficult-to-treat pediatric brain tumors recognizable to the immune system, this research lays important groundwork for future therapies aimed at improving outcomes for children facing these devastating cancers. Learn more here: jci.org/articles/view/196753

I'm maintaining an active list of biology-related job openings at various levels (PIs, staff scientists, postdocs, PhDs, etc.). Please feel free to subscribe or contribute! github.com/brianpenghe/Bio-J…

Together with @BrianHie's lab, we are looking for a lab manager to join the team @arcinstitute. If you love to organize, optimize, and accelerate scientific discovery, please consider applying! job-boards.greenhouse.io/arc…

Honored to receive a CRI STAR Award! Immensely grateful to the @CancerResearch Institute for backing bold ideas and supporting our mission to decode the rules of T cell signaling and make in vivo T cell reprogramming a reality. Excited for what comes next! 🚀

Excited to share our research about PP2A regulates immunogenic senescence for pediatric brain cancer.@UCSFCancer

Yes, Telemedicine Can Reduce Alcohol Use for Liver Disease Patients ucsf.edu/news/2026/06/432141…

Can We Convince the Body’s “Big Eater” Cells to Devour Tumors? Dr. Roarke Kamber earns funding for research that directs the immune system’s “big eaters,” macrophages, to eat tumor cells. ucsf.edu/news/2026/06/432106…

‼️The American Surgical Association bestowed the prestigious 2⃣0⃣2⃣6⃣ Flance-Karl Award upon @UCSFTransplant Surgeon Dr. Sandy Feng (@SandyFeng8) — our Vice Chair of Research — recognizing research with lasting clinical impact on the field of transplantation👏

💫 Congrats to Dr. Qizhi Tang, Professor of #Surgery in our @UCSFTransplant Division, on her appointment to the Bluestone and Rosenkrantz Immune Tolerance Professorship in Diabetes. This professorship is recognition of her pioneering work in immune tolerance research👏

California advances $12 billion bond for science research in rebuke to Trump cuts missionlocal.org/2026/05/cal… via @MLNow

Autoantibody assay refines EBV-RMS risk Neurology(R) reports an autoantibody diagnostic assay tuned to a consensus motif to predict risk of EBV-related multiple sclerosis—aiming for earlier, more stratified identification. Earlier ris… pubmed.ncbi.nlm.nih.gov/4182…

Truly an honor to receive the @AmerSurg-European Surgical Association Exchange Award in Rome last week. 🙏🏽 to the leaders of both societies and gracious hosts at San Raffaele and Humanitas! 🇮🇹@Massimo04868945 @TorzilliGuido @StefanoCrippa6 @spartelli @lelecapurso #ESA2026